• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

类固醇相关副作用:多发性骨髓瘤治疗中症状管理的最新进展

Steroid-Associated Side Effects: A Symptom Management Update on Multiple Myeloma Treatment
.

作者信息

King Tracy, Faiman Beth

机构信息

New South Wales Health Pathology.

Cleveland Clinic Taussig Cancer Institute.

出版信息

Clin J Oncol Nurs. 2017 Apr 1;21(2):240-249. doi: 10.1188/17.CJON.240-249.

DOI:10.1188/17.CJON.240-249
PMID:28315528
Abstract

BACKGROUND: One constant and relatively unchanged aspect of treatment of multiple myeloma (MM) is the use of glucocorticosteroids, or steroids, which can cause a wide range of adverse side effects and harm patients' quality of life.
.

OBJECTIVES: The objective of this study was to provide updated recommendations on the management of steroid-associated side effects in patients with MM.
.

METHODS

A study of steroid-associated side effects in MM treatment regimens was reviewed to provide updated recommendations to healthcare professionals.

FINDINGS

Identifying the side effects of steroids and managing them promptly contribute to the success of steroid-containing regimens for patients with MM.

摘要

背景

在多发性骨髓瘤(MM)的治疗中,一个持续且相对未变的方面是使用糖皮质激素,即类固醇,其会引发广泛的不良副作用并损害患者的生活质量。

目的

本研究的目的是就MM患者中类固醇相关副作用的管理提供最新建议。

方法

对MM治疗方案中类固醇相关副作用的研究进行了综述,以向医疗专业人员提供最新建议。

研究结果

识别类固醇的副作用并及时进行管理有助于含类固醇方案对MM患者治疗的成功。

相似文献

1
Steroid-Associated Side Effects: A Symptom Management Update on Multiple Myeloma Treatment
.类固醇相关副作用:多发性骨髓瘤治疗中症状管理的最新进展
Clin J Oncol Nurs. 2017 Apr 1;21(2):240-249. doi: 10.1188/17.CJON.240-249.
2
Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.多发性骨髓瘤患者中与类固醇相关的副作用:国际骨髓瘤基金会护士领导委员会共识声明
Clin J Oncol Nurs. 2008 Jun;12(3 Suppl):53-63. doi: 10.1188/08.CJON.S1.53-62.
3
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.与用于多发性骨髓瘤的靶向抗癌疗法硼替佐米和来那度胺相关的皮肤不良反应:新药,旧副作用。
Cutan Ocul Toxicol. 2014 Mar;33(1):1-6. doi: 10.3109/15569527.2013.787086. Epub 2013 May 2.
4
Diarrhea in Multiple Myeloma: A Review of the Literature.多发性骨髓瘤中的腹泻:文献综述
Clin J Oncol Nurs. 2016 Aug 1;20(4):E100-5. doi: 10.1188/16.CJON.E100-E105.
5
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.新型药物治疗多发性骨髓瘤不良事件的预防和管理:欧洲骨髓瘤网络的共识。
Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2.
6
Evidence-Based Guidelines for Preventing and Managing Side Effects of Multiple Myeloma.多发性骨髓瘤副作用预防与管理的循证指南
Semin Oncol Nurs. 2017 Aug;33(3):332-347. doi: 10.1016/j.soncn.2017.05.008. Epub 2017 Jul 18.
7
[Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].[评估我院硼替佐米治疗方案对多发性骨髓瘤有效性和安全性的观察性回顾性研究]
Farm Hosp. 2012 Jul-Aug;36(4):275-81. doi: 10.1016/j.farma.2011.06.019. Epub 2011 Nov 23.
8
Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board.多发性骨髓瘤新型疗法副作用的管理:国际骨髓瘤基金会护士领导委员会制定的共识声明
Clin J Oncol Nurs. 2008 Jun;12(3 Suppl):9-12. doi: 10.1188/08.CJON.S1.9-12.
9
Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.多发性骨髓瘤患者新型疗法相关的胃肠道副作用:国际骨髓瘤基金会护士领导委员会共识声明
Clin J Oncol Nurs. 2008 Jun;12(3 Suppl):37-52. doi: 10.1188/08.CJON.S1.37-51.
10
Adverse effects of androgen-deprivation therapy in prostate cancer and their management.雄激素剥夺疗法在前列腺癌中的不良反应及其管理。
BJU Int. 2015 Apr;115 Suppl 5:3-13. doi: 10.1111/bju.12964.

引用本文的文献

1
Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group.多发性骨髓瘤患者挽救性自体干细胞移植后使用卡非佐米和地塞米松维持治疗的健康相关生活质量及质量调整无进展生存期:北欧骨髓瘤研究组的一项随机2期试验
J Patient Rep Outcomes. 2024 Feb 5;8(1):15. doi: 10.1186/s41687-024-00691-2.
2
Anti-Angiogenic Activity of Drugs in Multiple Myeloma.药物在多发性骨髓瘤中的抗血管生成活性。
Cancers (Basel). 2023 Mar 27;15(7):1990. doi: 10.3390/cancers15071990.
3
Lifestyle considerations in multiple myeloma.
多发性骨髓瘤的生活方式考虑因素。
Blood Cancer J. 2021 Oct 26;11(10):172. doi: 10.1038/s41408-021-00560-x.
4
Are mesenchymal stem cells able to manage cytokine storm in COVID-19 patients? A review of recent studies.间充质干细胞能否应对新冠肺炎患者的细胞因子风暴?近期研究综述。
Regen Ther. 2021 Dec;18:152-160. doi: 10.1016/j.reth.2021.05.007. Epub 2021 Jun 8.
5
Promoting exercise for patients with multiple myeloma: attitudes and practices of clinical haematologists.促进多发性骨髓瘤患者的运动:临床血液学家的态度和实践。
J Cancer Surviv. 2022 Jun;16(3):688-695. doi: 10.1007/s11764-021-01062-2. Epub 2021 Jun 11.
6
Critically ill patients with cancer: A clinical perspective.癌症重症患者:临床视角
World J Clin Oncol. 2020 Oct 24;11(10):809-835. doi: 10.5306/wjco.v11.i10.809.
7
Patient-Reported Outcomes and Assessment of Quality of Life: A Focus on Multiple Myeloma.患者报告的结局与生活质量评估:聚焦多发性骨髓瘤
J Adv Pract Oncol. 2020 Jul;11(5):513-520. doi: 10.6004/jadpro.2020.11.5.7. Epub 2020 Jul 1.
8
Incidence and Risk Factors of Osteonecrosis of Femoral Head in Multiple Myeloma Patients Undergoing Dexamethasone-Based Regimens.基于地塞米松方案的多发性骨髓瘤患者股骨头坏死的发生率及危险因素。
Biomed Res Int. 2020 May 16;2020:7126982. doi: 10.1155/2020/7126982. eCollection 2020.